title: Guidelines on the use of gelatin sponge particles in embolotherapy.
abstract: Gelatin sponge (GS) is one of the most widely used embolic agents in interventional procedures. There are four commercially available GS products in Japan; however, the endovascular use of Gelfoam and Spongel is off-label, and Gelpart can only be used for hepatic artery embolization and Serescue can only be used for hemostasis of arterial bleeding. GS has been used for a variety of clinical indications, mainly tumor embolization and stopping massive arterial bleeding. The optimal size and preparation procedure of GS particles differs slightly for each clinical indication. In addition, there is a risk of ischemic and/or infectious complications associated with GS embolization in various situations. Therefore, radiologists should be familiar with not only the preparation and handling of GS particles, but also the disadvantages and potential risks, in order to perform GS embolization safely and effectively.
authors: Department of Diagnostic Radiology, Fukuiken Saiseikai Hospital, 7-1 Wadanaka-cho, Funabashi, Fukui, 918-8503, Japan, s-miyayama@fukui.saiseikai.or.jp.
authors: Shiro
authors: S
authors: Miyayama
authors: Koichiro
authors: K
authors: Yamakado
authors: Hiroshi
authors: H
authors: Anai
authors: Daisuke
authors: D
authors: Abo
authors: Tetsuya
authors: T
authors: Minami
authors: Haruyuki
authors: H
authors: Takaki
authors: Taishi
authors: T
authors: Kodama
authors: Takashi
authors: T
authors: Yamanaka
authors: Hideyuki
authors: H
authors: Nishiofuku
authors: Kengo
authors: K
authors: Morimoto
authors: Takeshi
authors: T
authors: Soyama
authors: Yu
authors: Y
authors: Hasegawa
authors: Koichi
authors: K
authors: Nakamura
authors: Tomoaki
authors: T
authors: Yamanishi
authors: Morio
authors: M
authors: Sato
authors: Yasuo
authors: Y
authors: Nakajima
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced; D000818:Animals; D004621:Embolization, Therapeutic / Q000009:adverse effects / Q000379:methods*; D005781:Gelatin Sponge, Absorbable / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000628:therapy*; D006490:Hemostatics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007564:Japan; D009369:Neoplasms / Q000628:therapy*; D010146:Pain / Q000209:etiology; D017410:Practice Guidelines as Topic
chemical_list: D006490:Hemostatics